Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Autores: Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; Bagur, Alicia Cristina; Oliveri, María Beatriz; Zanchetta, M. B.; Farias, V.; Maffei, L.; Premrou, V.; Mansur, J. L.; larroude, M. S.; Sarli, M. A.; Rey, P.; Ulla, M. R.; Pavlove, M. M.; Karlsbrum, S.; Brance, María Lorena
Año de publicación: 2016
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naï¿½ve patients (BP-naï¿½ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naï¿½ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ï¿½ SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naï¿½ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naï¿½ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina
Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina
Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina
Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina
Fil: Farias, V.. Universidad del Salvador; Argentina
Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina
Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina
Fil: Sarli, M. A.. Universidad del Salvador; Argentina
Fil: Rey, P.. Universidad del Salvador; Argentina
Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina
Fil: Pavlove, M. M.. Hospital Durand; Argentina
Fil: Karlsbrum, S.. Hospital Durand; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina
Materia: DENOSUMAB
BONE MINERAL DENSITY
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/55323

Acceder

id	CONICETDig_52887b8b5b4a7ed59d84d4e29c519ceb
oai_identifier_str	oai:ri.conicet.gov.ar:11336/55323
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisSánchez, ArielBrun, Lucas Ricardo MartínSalerni, H.Costanzo, P. R.Gonzalez, D.Bagur, Alicia CristinaOliveri, María BeatrizZanchetta, M. B.Farias, V.Maffei, L.Premrou, V.Mansur, J. L.larroude, M. S.Sarli, M. A.Rey, P.Ulla, M. R.Pavlove, M. M.Karlsbrum, S.Brance, María LorenaDENOSUMABBONE MINERAL DENSITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naï¿½ve patients (BP-naï¿½ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naï¿½ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ï¿½ SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naï¿½ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naï¿½ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Gonzalez, D.. Mautalen Salud E Investigación; ArgentinaFil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; ArgentinaFil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; ArgentinaFil: Zanchetta, M. B.. Universidad del Salvador; ArgentinaFil: Farias, V.. Universidad del Salvador; ArgentinaFil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; ArgentinaFil: larroude, M. S.. Cesar Milstein Hospital; ArgentinaFil: Sarli, M. A.. Universidad del Salvador; ArgentinaFil: Rey, P.. Universidad del Salvador; ArgentinaFil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; ArgentinaFil: Pavlove, M. M.. Hospital Durand; ArgentinaFil: Karlsbrum, S.. Hospital Durand; ArgentinaFil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; ArgentinaHindawi Limited2016-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/55323Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-62042-0064CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:52:03Zoai:ri.conicet.gov.ar:11336/55323instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:52:03.329CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
spellingShingle	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis Sánchez, Ariel DENOSUMAB BONE MINERAL DENSITY
title_short	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_fullStr	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full_unstemmed	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_sort	Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
dc.creator.none.fl_str_mv	Sánchez, Ariel Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena
author	Sánchez, Ariel
author_facet	Sánchez, Ariel Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena
author_role	author
author2	Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena
author2_role	author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	DENOSUMAB BONE MINERAL DENSITY
topic	DENOSUMAB BONE MINERAL DENSITY
purl_subject.fl_str_mv	https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv	The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naï¿½ve patients (BP-naï¿½ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naï¿½ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ï¿½ SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naï¿½ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naï¿½ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina Fil: Farias, V.. Universidad del Salvador; Argentina Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina Fil: Sarli, M. A.. Universidad del Salvador; Argentina Fil: Rey, P.. Universidad del Salvador; Argentina Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina Fil: Pavlove, M. M.. Hospital Durand; Argentina Fil: Karlsbrum, S.. Hospital Durand; Argentina Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina
description	The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naï¿½ve patients (BP-naï¿½ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naï¿½ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ï¿½ SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naï¿½ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naï¿½ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
publishDate	2016
dc.date.none.fl_str_mv	2016-08
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/55323 Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6 2042-0064 CONICET Digital CONICET
url	http://hdl.handle.net/11336/55323
identifier_str_mv	Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6 2042-0064 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959 info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf application/pdf application/pdf application/pdf
dc.publisher.none.fl_str_mv	Hindawi Limited
publisher.none.fl_str_mv	Hindawi Limited
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1844613598379245568
score	13.070432

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Publicaciones similares